CND Life Sciences Gains New York CLEP Permit, Expanding Access to Neurodiagnostic Tools

According to a recent LinkedIn post from CND Life Sciences, the company has received a Clinical Laboratory Evaluation Program (CLEP) laboratory permit from the New York State Department of Health, described as a national benchmark of laboratory excellence. The post suggests this authorization will expand clinician access to CND’s neurodiagnostic tools for patients across New York State.

The LinkedIn post highlights that CLEP approval is being positioned as validation of CND’s scientific rigor and operational quality in neurology-focused diagnostic testing. For investors, broader New York market access and enhanced regulatory credibility could support higher test volumes, strengthen payer and provider relationships, and improve the company’s competitive standing in neurodiagnostics, particularly in areas such as Parkinson’s disease and related disorders.